Algorithm for the use of inhaled therapies in COPD using the GOLD Guidelines

Patients with co-existing Asthma and COPD may need to be managed differently. This algorithm is intended for the management of patients with pure COPD only.

**GOLD Category C (Low symptoms and High Risk)**

- LAMA/ LABA Combination
  - Continue SABA prn.
  - Aclidinium/Formoterol (Duaklir Genuair DPI) 375/12 one puff BD OR
  - Tiotropium / Olodaterol (Spiolto Respimat SMI) 2.5mcg/2.5mcg two puffs OD OR
  - Umeclidinium/Vilanterol (Anoro Ellipta DPI) 55/22mcg one puff OD

If the patient remains symptomatic consider ICS/LABA and LAMA

**GOLD Category D (High symptoms and High Risk)**

If all other treatment options have been tried (including pulmonary rehabilitation) and the patient is still symptomatic and/or exacerbating frequently, offer an ICS/LABA combination plus LAMA. Continue SABA prn.

- Beclometasone/Formoterol (Fostair pMDI 100/6-two puffs BD / Nexthaler DPI 100/6 two puffs BD OR
- Budesonide/Formoterol (Duoresp Spiromax 320/9 one puff BD DPI) OR
- Fluticasone Furoate/Vilanterol (Relvar Ellipta DPI) 92/22 one puff OD

**SABA or SAMA**

Offer Short Acting Beta Agonist (SABA) or a Short Acting Antimuscarinic Agent (SAMA) when required.

- Salbutamol 100mcg/dose – Two puffs when required up to four times a day (pMDI must be used with a spacer)

**Alternative Options:**

- Easyhaler® Salbutamol 100mcg/actuation (dry powder) – Two puffs when required up to four times a day OR
- Ipratropium 20mcg Inhaler - Two puffs when required up to four times a day (pMDI must be used with a spacer)

If patient remains symptomatic consider LAMA

Eklira Genuair, Spiriva Respimat, Incruse Ellipta

This document has been adapted for local use from the COPD Management in Primary Care – Inhaled Therapies produced by Oxfordshire Clinical Commissioning Group, the West Berkshire Respiratory Group and the Algorithm for use of inhaled therapies in COPD produced by the Southwark and Lambeth Clinical Commissioning Groups.

Approved by Frimley Health Area Prescribing Committee, November 2016

Review date November 2018